论文部分内容阅读
检测了３７例Ｇｒａｖｅｓ病患者血清甲状腺刺激免疫球蛋白（ＴＳＩ）、甲状腺生长免疫球蛋白（ＴＧＩ）和外周血总Ｔ细胞（ＣＤ３）、辅助性／诱导性Ｔ细胞（ＣＤ４）及抑制性／细胞毒性Ｔ细胞（ＣＤ８），并以３２例正常人作对照．发现Ｇｒａｖｅｓ病ＴＳＩ阳性率８３．８％，ＴＧＩ阳性率５８．３０，ＴＳＩ活性与血清ＴＴ４含量呈正相关（Ｐ＜０．０１），ＴＧＩ活性随甲状腺肿大加重而升高．外周血ＣＤ３＋、ＣＤ８＋百分率降低（Ｐ＜０．０１），ＣＤ４＋／ＣＤ８＋比值增高（Ｐ＜０．０５）．其中１８例经他巴唑治疗，甲状腺功能恢复明显，ＴＳＩ活性明显下降，而ＴＧＩ活性、ＣＤ３＋、ＣＤ８＋百分率和ＣＤ４＋／ＣＤ８＋比值无显著变化．对ＴＳＩ、ＴＧＩ及Ｔ细胞亚群在Ｇｒａｖｅｓ病发病中的作用及其临床意义作了讨论．
Serum levels of thyroid-stimulated immunoglobulin (TSI), thyroid gland growth immunoglobulin (TGI) and total peripheral T cells (CD3), helper / inducible T cells (CD4) and inhibitory cells T cells (CD8), and 32 normal controls. The positive rate of TSI was 83.8% and the positive rate of TGI was 58.30 in Graves’ disease. TSI activity was positively correlated with serum TT4 level (P <0.01). TGI activity increased with goiter. The percentage of CD3 + and CD8 + in peripheral blood decreased (P <0.01) and the ratio of CD4 + / CD8 + increased (P <0.05). Among them, 18 cases were treated with methimazole, thyroid function recovered obviously, TSI activity decreased obviously, while TGI activity, CD3 +, CD8 + percentage and CD4 + / CD8 + ratio had no significant change. The role of TSI, TGI and T cell subsets in the pathogenesis of Graves disease and its clinical significance are discussed.